Lynnette Fallon Sells 5,091 Shares of ClearPoint Neuro (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Lynnette Fallon sold 5,091 shares of ClearPoint Neuro stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $11.14, for a total value of $56,713.74. Following the completion of the sale, the director owned 48,227 shares of the company’s stock, valued at $537,248.78. The trade was a 9.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ClearPoint Neuro Stock Up 4.5%

Shares of CLPT stock traded up $0.50 on Thursday, hitting $11.70. The stock had a trading volume of 404,706 shares, compared to its average volume of 719,147. The business has a 50 day moving average price of $10.55 and a 200 day moving average price of $12.88. ClearPoint Neuro, Inc. has a one year low of $8.27 and a one year high of $30.10. The company has a quick ratio of 4.88, a current ratio of 5.79 and a debt-to-equity ratio of 2.63. The company has a market cap of $350.88 million, a PE ratio of -11.58 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The company had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. Research analysts anticipate that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ClearPoint Neuro

A number of large investors have recently modified their holdings of CLPT. Caitong International Asset Management Co. Ltd purchased a new stake in shares of ClearPoint Neuro during the fourth quarter worth about $25,000. BNP Paribas Financial Markets grew its stake in shares of ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after acquiring an additional 2,143 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of ClearPoint Neuro during the second quarter worth about $35,000. Huntington National Bank purchased a new stake in shares of ClearPoint Neuro during the third quarter worth about $44,000. Finally, Russell Investments Group Ltd. grew its stake in shares of ClearPoint Neuro by 1,079.0% during the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after acquiring an additional 2,158 shares during the last quarter. Hedge funds and other institutional investors own 30.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CLPT. B. Riley Financial lifted their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Finally, Stifel Nicolaus began coverage on ClearPoint Neuro in a research note on Friday, May 8th. They issued a “buy” rating and a $16.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $18.00.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.